Caveolin‑1  ||| S:0 E:11 ||| NNP
is  ||| S:11 E:14 ||| VBZ
essential  ||| S:14 E:24 ||| JJ
in  ||| S:24 E:27 ||| IN
the  ||| S:27 E:31 ||| DT
differentiation  ||| S:31 E:47 ||| NN
of  ||| S:47 E:50 ||| IN
human  ||| S:50 E:56 ||| JJ
adipose‑derived  ||| S:56 E:72 ||| CD
stem  ||| S:72 E:77 ||| NN
cells  ||| S:77 E:83 ||| NNS
into  ||| S:83 E:88 ||| IN
hepatocyte‑like  ||| S:88 E:104 ||| CD
cells  ||| S:104 E:110 ||| NNS
via  ||| S:110 E:114 ||| IN
an  ||| S:114 E:117 ||| DT
MAPK  ||| S:117 E:122 ||| NNP
pathway‑dependent  ||| S:122 E:140 ||| NNP
mechanism  ||| S:140 E:150 ||| NN
Human  ||| S:150 E:156 ||| NNP
adipose‑derived  ||| S:156 E:172 ||| NNP
stem  ||| S:172 E:177 ||| NN
cells  ||| S:177 E:183 ||| NNS
( ||| S:183 E:184 ||| -LRB-
hADSCs ||| S:184 E:190 ||| NNP
) ||| S:190 E:191 ||| -RRB-
,  ||| S:191 E:193 ||| ,
widely  ||| S:193 E:200 ||| RB
present  ||| S:200 E:208 ||| VB
in  ||| S:208 E:211 ||| IN
the  ||| S:211 E:215 ||| DT
adult  ||| S:215 E:221 ||| JJ
human  ||| S:221 E:227 ||| JJ
body ||| S:227 E:231 ||| NN
,  ||| S:231 E:233 ||| ,
are  ||| S:233 E:237 ||| VBP
an  ||| S:237 E:240 ||| DT
emerging  ||| S:240 E:249 ||| VBG
and  ||| S:249 E:253 ||| CC
attractive  ||| S:253 E:264 ||| JJ
tool  ||| S:264 E:269 ||| NN
for  ||| S:269 E:273 ||| IN
the  ||| S:273 E:277 ||| DT
establishment  ||| S:277 E:291 ||| NN
of  ||| S:291 E:294 ||| IN
stem  ||| S:294 E:299 ||| CD
cell‑based  ||| S:299 E:310 ||| CD
therapies  ||| S:310 E:320 ||| NNS
for  ||| S:320 E:324 ||| IN
the  ||| S:324 E:328 ||| DT
treatment  ||| S:328 E:338 ||| NN
of  ||| S:338 E:341 ||| IN
liver  ||| S:341 E:347 ||| JJ
disease ||| S:347 E:354 ||| NN
.  ||| S:354 E:356 ||| .
However ||| S:356 E:363 ||| RB
,  ||| S:363 E:365 ||| ,
the  ||| S:365 E:369 ||| DT
mechanism  ||| S:369 E:379 ||| NN
underlying  ||| S:379 E:390 ||| VBG
hADSCs  ||| S:390 E:397 ||| JJ
hepatic  ||| S:397 E:405 ||| JJ
differentiation  ||| S:405 E:421 ||| NN
remains  ||| S:421 E:429 ||| VBZ
to  ||| S:429 E:432 ||| TO
be  ||| S:432 E:435 ||| VB
elucidated ||| S:435 E:445 ||| NNS
.  ||| S:445 E:447 ||| .
Caveolin‑1  ||| S:447 E:458 ||| NNP
( ||| S:458 E:459 ||| -LRB-
Cav‑1 ||| S:459 E:464 ||| NNP
) ||| S:464 E:465 ||| -RRB-
,  ||| S:465 E:467 ||| ,
a  ||| S:467 E:469 ||| DT
21‑24 kDa  ||| S:469 E:479 ||| JJ
membrane  ||| S:479 E:488 ||| JJ
structural  ||| S:488 E:499 ||| JJ
protein ||| S:499 E:506 ||| NN
,  ||| S:506 E:508 ||| ,
is  ||| S:508 E:511 ||| VBZ
important  ||| S:511 E:521 ||| JJ
in  ||| S:521 E:524 ||| IN
liver  ||| S:524 E:530 ||| JJ
regeneration  ||| S:530 E:543 ||| NN
and  ||| S:543 E:547 ||| CC
development ||| S:547 E:558 ||| NN
.  ||| S:558 E:560 ||| .
In  ||| S:560 E:563 ||| IN
the  ||| S:563 E:567 ||| DT
present  ||| S:567 E:575 ||| JJ
study ||| S:575 E:580 ||| NN
,  ||| S:580 E:582 ||| ,
fluorescence  ||| S:582 E:595 ||| JJ
immunocytochemistry  ||| S:595 E:615 ||| NN
and  ||| S:615 E:619 ||| CC
western  ||| S:619 E:627 ||| JJ
blotting  ||| S:627 E:636 ||| NN
were  ||| S:636 E:641 ||| VBD
used  ||| S:641 E:646 ||| VBN
to  ||| S:646 E:649 ||| TO
analyze  ||| S:649 E:657 ||| VB
the  ||| S:657 E:661 ||| DT
expression  ||| S:661 E:672 ||| NN
levels  ||| S:672 E:679 ||| NNS
of  ||| S:679 E:682 ||| IN
Cav‑1  ||| S:682 E:688 ||| NNP
and  ||| S:688 E:692 ||| CC
evaluate  ||| S:692 E:701 ||| VB
its  ||| S:701 E:705 ||| PRP$
effects  ||| S:705 E:713 ||| NNS
on  ||| S:713 E:716 ||| IN
the  ||| S:716 E:720 ||| DT
hepatic  ||| S:720 E:728 ||| JJ
differentiation  ||| S:728 E:744 ||| NN
of  ||| S:744 E:747 ||| IN
hADSCs ||| S:747 E:753 ||| JJ
.  ||| S:753 E:755 ||| .
The  ||| S:755 E:759 ||| DT
results  ||| S:759 E:767 ||| NNS
revealed  ||| S:767 E:776 ||| VBD
that  ||| S:776 E:781 ||| DT
primary  ||| S:781 E:789 ||| JJ
hADSCs  ||| S:789 E:796 ||| NN
preserved  ||| S:796 E:806 ||| VBD
the  ||| S:806 E:810 ||| DT
ability  ||| S:810 E:818 ||| NN
to  ||| S:818 E:821 ||| TO
proliferate  ||| S:821 E:833 ||| VB
and  ||| S:833 E:837 ||| CC
differentiate  ||| S:837 E:851 ||| NN
into  ||| S:851 E:856 ||| IN
hepatocyte‑like  ||| S:856 E:872 ||| CD
cells ||| S:872 E:877 ||| NNS
.  ||| S:877 E:879 ||| .
As  ||| S:879 E:882 ||| RB
demonstrated  ||| S:882 E:895 ||| VBN
by  ||| S:895 E:898 ||| IN
semiquantitative  ||| S:898 E:915 ||| JJ
reverse  ||| S:915 E:923 ||| NN
transcription‑polymerase  ||| S:923 E:948 ||| CD
chain  ||| S:948 E:954 ||| NN
reaction ||| S:954 E:962 ||| NN
,  ||| S:962 E:964 ||| ,
hepatocyte‑inducing  ||| S:964 E:984 ||| CD
factors  ||| S:984 E:992 ||| NNS
significantly  ||| S:992 E:1006 ||| RB
increased  ||| S:1006 E:1016 ||| VBD
the  ||| S:1016 E:1020 ||| DT
expression  ||| S:1020 E:1031 ||| NN
of  ||| S:1031 E:1034 ||| IN
Cav‑1  ||| S:1034 E:1040 ||| CD
in  ||| S:1040 E:1043 ||| IN
a  ||| S:1043 E:1045 ||| DT
time‑dependent  ||| S:1045 E:1060 ||| JJ
manner ||| S:1060 E:1066 ||| NN
,  ||| S:1066 E:1068 ||| ,
as  ||| S:1068 E:1071 ||| RB
indicated  ||| S:1071 E:1081 ||| VBN
by  ||| S:1081 E:1084 ||| IN
increased  ||| S:1084 E:1094 ||| JJ
expression  ||| S:1094 E:1105 ||| NN
levels  ||| S:1105 E:1112 ||| NNS
of  ||| S:1112 E:1115 ||| IN
the  ||| S:1115 E:1119 ||| DT
albumin  ||| S:1119 E:1127 ||| NN
( ||| S:1127 E:1128 ||| -LRB-
ALB ||| S:1128 E:1131 ||| NNP
)  ||| S:1131 E:1133 ||| -RRB-
and  ||| S:1133 E:1137 ||| CC
α‑fetoprotein  ||| S:1137 E:1151 ||| NNP
( ||| S:1151 E:1152 ||| -LRB-
AFP ||| S:1152 E:1155 ||| NNP
)  ||| S:1155 E:1157 ||| -RRB-
markers ||| S:1157 E:1164 ||| NN
.  ||| S:1164 E:1166 ||| .
In  ||| S:1166 E:1169 ||| IN
addition  ||| S:1169 E:1178 ||| NN
the  ||| S:1178 E:1182 ||| DT
expression  ||| S:1182 E:1193 ||| NN
levels  ||| S:1193 E:1200 ||| NNS
of  ||| S:1200 E:1203 ||| IN
ALB  ||| S:1203 E:1207 ||| NNP
and  ||| S:1207 E:1211 ||| CC
HNF1A  ||| S:1211 E:1217 ||| NNP
significantly  ||| S:1217 E:1231 ||| RB
decreased  ||| S:1231 E:1241 ||| VBD
following  ||| S:1241 E:1251 ||| VBG
small  ||| S:1251 E:1257 ||| JJ
interfering  ||| S:1257 E:1269 ||| NNS
RNA‑mediated  ||| S:1269 E:1282 ||| VBP
knockdown  ||| S:1282 E:1292 ||| VBN
of  ||| S:1292 E:1295 ||| IN
Cav‑1 ||| S:1295 E:1300 ||| CD
.  ||| S:1300 E:1302 ||| .
The  ||| S:1302 E:1306 ||| DT
mitogen‑activated  ||| S:1306 E:1324 ||| JJ
protein  ||| S:1324 E:1332 ||| NN
kinase  ||| S:1332 E:1339 ||| NNS
( ||| S:1339 E:1340 ||| -LRB-
MAPK ||| S:1340 E:1344 ||| NNP
)  ||| S:1344 E:1346 ||| -RRB-
signaling  ||| S:1346 E:1356 ||| VBG
pathway  ||| S:1356 E:1364 ||| NNS
was  ||| S:1364 E:1368 ||| VBD
activated  ||| S:1368 E:1378 ||| VBN
during  ||| S:1378 E:1385 ||| IN
hepatic  ||| S:1385 E:1393 ||| JJ
differentiation  ||| S:1393 E:1409 ||| NN
and  ||| S:1409 E:1413 ||| CC
inhibited  ||| S:1413 E:1423 ||| VBD
following  ||| S:1423 E:1433 ||| VBG
Cav‑1  ||| S:1433 E:1439 ||| CD
knockdown ||| S:1439 E:1448 ||| NNS
.  ||| S:1448 E:1450 ||| .
These  ||| S:1450 E:1456 ||| DT
results  ||| S:1456 E:1464 ||| NNS
suggested  ||| S:1464 E:1474 ||| VBD
that  ||| S:1474 E:1479 ||| IN
Cav‑1  ||| S:1479 E:1485 ||| NNP
may  ||| S:1485 E:1489 ||| MD
regulate  ||| S:1489 E:1498 ||| VB
the  ||| S:1498 E:1502 ||| DT
hepatocyte‑like  ||| S:1502 E:1518 ||| JJ
differentiation  ||| S:1518 E:1534 ||| NN
of  ||| S:1534 E:1537 ||| IN
hADSCs  ||| S:1537 E:1544 ||| JJ
by  ||| S:1544 E:1547 ||| IN
modulating  ||| S:1547 E:1558 ||| FW
mitogen‑activated  ||| S:1558 E:1576 ||| FW
protein  ||| S:1576 E:1584 ||| FW
kinase  ||| S:1584 E:1591 ||| FW
kinase ||| S:1591 E:1597 ||| FW
/ ||| S:1597 E:1598 ||| FW
MAPK  ||| S:1598 E:1603 ||| FW
signaling ||| S:1603 E:1612 ||| FW
.  ||| S:1612 E:1614 ||| .
The  ||| S:1614 E:1618 ||| DT
results  ||| S:1618 E:1626 ||| NNS
of  ||| S:1626 E:1629 ||| IN
the  ||| S:1629 E:1633 ||| DT
present  ||| S:1633 E:1641 ||| JJ
study  ||| S:1641 E:1647 ||| NN
will  ||| S:1647 E:1652 ||| MD
provide  ||| S:1652 E:1660 ||| VB
experimental  ||| S:1660 E:1673 ||| JJ
and  ||| S:1673 E:1677 ||| CC
theoretical  ||| S:1677 E:1689 ||| JJ
basis  ||| S:1689 E:1695 ||| NN
for  ||| S:1695 E:1699 ||| IN
further  ||| S:1699 E:1707 ||| JJ
clinical  ||| S:1707 E:1716 ||| JJ
studies  ||| S:1716 E:1724 ||| NNS
on  ||| S:1724 E:1727 ||| IN
stem  ||| S:1727 E:1732 ||| JJ
cell  ||| S:1732 E:1737 ||| NN
transplantation  ||| S:1737 E:1753 ||| NN
in  ||| S:1753 E:1756 ||| IN
the  ||| S:1756 E:1760 ||| DT
treatment  ||| S:1760 E:1770 ||| NN
of  ||| S:1770 E:1773 ||| IN
liver  ||| S:1773 E:1779 ||| JJ
disease ||| S:1779 E:1786 ||| NN
.  ||| S:1786 E:1788 ||| .
